ARD103
Phase 2Biologic
ARD103 is one of 9 biologic programs targeting R/R AML. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in R/R AML
#DrugCompanyPhaseTrials
1Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Ibrance
PfizerPhase 1
Komzifti
KKura Oncology, Inc.
Phase 1
Tazverik
EEpizyme, Inc.
Phase 1
Mezigdomide
Bristol-Myers SquibbPhase 1
Liposome-Encapsulated Daunorubicin-Cytarabine
MM.D. Anderson Cancer Center
Phase 1
ARD103
AARCE Therapeutics, Inc.
Phase 2
Hydroxycarbamid
TTheravia
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ARD103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- AARCE Therapeutics, Inc.